Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma

NCT02998268 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT02998268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02998268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 7, 2017
Completion date
March 31, 2026
Enrollment
42 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma